Bioequivalence of a Fixed Dose Combination Tablet of Dolutegravir and Rilpivirine in Healthy Subjects

Conference Reports for NATAP

18th International Workshop on
Clinical Pharmacology of Antiviral Therapy
June 14-17, 2017
Chicago, Ill.C


Bioequivalence of a Fixed Dose Combination Tablet of Dolutegravir and Rilpivirine in Healthy Subjects

	Reported by Jules Levin 18th International Workshop on Clinical Pharmacology of Antiviral Therapy, June 14-17, 2017, Chicago CROI: SWORD 1 & 2: Switch to DTG + RPV Maintains Virologic Suppression Through 48 Weeks, a Phase III Study - (02/16/17)